Home > Insider Trading > Filing (0001209191-22-040104)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1490829	James Jones	2525 West End Avenue Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-06-01	38	$2.05	21,439	No	4	P	Direct
Common Stock	Acquisiton	2022-06-02	38	$2.08	21,477	No	4	P	Direct
Common Stock	Acquisiton	2022-06-03	38	$2.09	21,515	No	4	P	Direct
Common Stock	Acquisiton	2022-06-06	40	$2.07	21,555	No	4	P	Direct
Common Stock	Acquisiton	2022-06-07	30	$2.08	21,585	No	4	P	Direct
Common Stock	Acquisiton	2022-06-08	40	$2.12	21,625	No	4	P	Direct
Common Stock	Acquisiton	2022-06-09	40	$2.09	21,665	No	4	P	Direct
Common Stock	Acquisiton	2022-06-10	40	$2.04	21,705	No	4	P	Direct
Common Stock	Acquisiton	2022-06-13	40	$2.01	21,745	No	4	P	Direct
Common Stock	Acquisiton	2022-06-14	40	$2.02	21,785	No	4	P	Direct
Common Stock	Acquisiton	2022-06-15	40	$1.98	21,825	No	4	P	Direct
Common Stock	Acquisiton	2022-06-16	40	$1.95	21,865	No	4	P	Direct
Common Stock	Acquisiton	2022-06-17	40	$1.94	21,905	No	4	P	Direct
Common Stock	Acquisiton	2022-06-21	42	$1.97	21,947	No	4	P	Direct
Common Stock	Acquisiton	2022-06-22	39	$1.99	21,986	No	4	P	Direct
Common Stock	Acquisiton	2022-06-23	42	$2.01	22,028	No	4	P	Direct
Common Stock	Acquisiton	2022-06-24	42	$2.11	22,070	No	4	P	Direct
Common Stock	Acquisiton	2022-06-27	7	$2.06	22,077	No	4	P	Direct
Common Stock	Acquisiton	2022-06-28	37	$2.06	22,114	No	4	P	Direct
Common Stock	Acquisiton	2022-06-29	42	$2.11	22,156	No	4	P	Direct
Common Stock	Acquisiton	2022-06-30	42	$2.08	22,198	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.